Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. Show More...
-
Website http://www.salariuspharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.76 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -52.0 -60.75 -49.75 -30.5 -2.12 0.66 Dividends USD Payout Ratio % * Shares Mil 1.0 1.0 1.0 1.0 3.0 5.0 Book Value Per Share * USD 98.41 50.82 15.29 2.16 1.32 Free Cash Flow Per Share * USD -49.68 -41.96 -36.62 -4.96 Return on Assets % -44.6 -49.9 -70.12 -96.61 -57.13 -48.07 Financial Leverage (Average) 1.03 1.07 1.2 1.12 1.31 1.11 Return on Equity % -68.04 -52.13 -77.88 -114.21 -69.84 -53.72 Return on Invested Capital % -68.04 -52.13 -77.88 -114.21 -66.48 -52.67 Interest Coverage Current Ratio 32.4 16.06 5.91 9.32 1.42 5.28 Quick Ratio 32.08 15.71 5.69 8.89 1.13 4.96 Debt/Equity